Tresiba study for 2.5 years Type 2 Diabetes

New data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) show that the majority of type 2 diabetes patients receiving the recently launched Tresiba (insulin degludec) from Novo Nordisk plus metformin, were able to maintain good glycaemic control for 2.5 years. Specifically, 80.5% of those patients who were in good glycaemic control after 2 years with Tresiba plus metformin maintained HbA1c below 7% when continuing treatment with Tresiba and metformin only, in a further 26-week add-on study. The data also confirm the durability and efficacy of the long-acting basal insulin Tresiba, and furthermore demonstrates that the addition of Victoza (liraglutide) is highly effective in helping patients achieve their glycaemic targets.